🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B

Recruitingn/aAges 20 Years - anyAllTaichung Veterans General Hospital
NCT05583006 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chronic hepatitis B (CHB) patients may be unsatisfied to entecavir (ETV) therapy due to the inconvenience in drug taking, i.e., fasting for more than 2 hours and/or dose adjustment according to estimated glomerular filtration rate (eGFR). However, tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with CHB, and is convenient in drug taking, i.e., once daily regardless food taking and renal function.Therefore,TAF can be a good option in CHB patients who are unsatisfied to ETV therapy. The aim of this prospective cohort study is to assess the improvement on satisfaction (including drug adherence) of TAF switch therapy in CHB patients who are unsatisfied to ETV therapy. In addition, with expected adherence improvement in TAF switch therapy, the efficacy of TAF switch therapy may be improved, and the efficacy benefits can be evaluated by the changes of

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. At least 20 years of age 2. Detectable serum HBsAg 3. Chronic HBV infection under ETV therapy 4. ETV users who are unsatisfied with the efficacy and/or feel inconvenient of ETV therapy 5. No contraindications for TAF switch therapy 6. HBV antiviral period expectancy for at least 1 year Exclusion Criteria: 1. End stage renal disease (estimated glomerular filtration rate \[eGRF\]\< 15 mL/min/1.73m2) without dialysis 2. Co-infected with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus 3. Any active malignancies 4. Under immunosuppressants 5. Known allergy to tenofovir-contained regimens
💊

What it tests

  • tenofovir alafenamide (TAF)
📍

Where

1 site
Taichung Veterans General Hospital
Taichung, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy